Logo image of SNGX

SOLIGENIX INC (SNGX) Stock Fundamental Analysis

USA - NASDAQ:SNGX - US8342236044 - Common Stock

1.5463 USD
-0.01 (-0.88%)
Last: 10/29/2025, 12:34:57 PM
Fundamental Rating

2

SNGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNGX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

SNGX had negative earnings in the past year.
SNGX had a negative operating cash flow in the past year.
SNGX had negative earnings in each of the past 5 years.
SNGX had a negative operating cash flow in each of the past 5 years.
SNGX Yearly Net Income VS EBIT VS OCF VS FCFSNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

SNGX has a worse Return On Assets (-184.80%) than 88.95% of its industry peers.
SNGX has a Return On Equity of -582.04%. This is in the lower half of the industry: SNGX underperforms 78.84% of its industry peers.
Industry RankSector Rank
ROA -184.8%
ROE -582.04%
ROIC N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SNGX Yearly ROA, ROE, ROICSNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNGX Yearly Profit, Operating, Gross MarginsSNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

5

2. Health

2.1 Basic Checks

SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNGX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SNGX has been increased compared to 5 years ago.
Compared to 1 year ago, SNGX has an improved debt to assets ratio.
SNGX Yearly Shares OutstandingSNGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SNGX Yearly Total Debt VS Total AssetsSNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

SNGX has an Altman-Z score of -62.57. This is a bad value and indicates that SNGX is not financially healthy and even has some risk of bankruptcy.
SNGX has a worse Altman-Z score (-62.57) than 94.57% of its industry peers.
SNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -62.57
ROIC/WACCN/A
WACC8.73%
SNGX Yearly LT Debt VS Equity VS FCFSNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

SNGX has a Current Ratio of 1.47. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
SNGX has a Current ratio of 1.47. This is amonst the worse of the industry: SNGX underperforms 81.46% of its industry peers.
SNGX has a Quick Ratio of 1.47. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.47, SNGX is not doing good in the industry: 80.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
SNGX Yearly Current Assets VS Current LiabilitesSNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

3

3. Growth

3.1 Past

SNGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.57%, which is quite impressive.
The Revenue for SNGX has decreased by -100.00% in the past year. This is quite bad
Measured over the past years, SNGX shows a very negative growth in Revenue. The Revenue has been decreasing by -51.88% on average per year.
EPS 1Y (TTM)63.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.4%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%

3.2 Future

SNGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.16% yearly.
Based on estimates for the next years, SNGX will show a small growth in Revenue. The Revenue will grow by 6.88% on average per year.
EPS Next Y53.09%
EPS Next 2Y32.34%
EPS Next 3Y21.16%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SNGX Yearly Revenue VS EstimatesSNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2M 4M 6M 8M 10M
SNGX Yearly EPS VS EstimatesSNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500 -1K -1.5K

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNGX Price Earnings VS Forward Price EarningsSNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNGX Per share dataSNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

SNGX's earnings are expected to grow with 21.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.34%
EPS Next 3Y21.16%

0

5. Dividend

5.1 Amount

No dividends for SNGX!.
Industry RankSector Rank
Dividend Yield N/A

SOLIGENIX INC

NASDAQ:SNGX (10/29/2025, 12:34:57 PM)

1.5463

-0.01 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners4.48%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0.5%
Market Cap12.94M
Revenue(TTM)N/A
Net Income(TTM)-10645600
Analysts82.86
Price Target22.95 (1384.19%)
Short Float %13.02%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.24%
Min EPS beat(2)-55.11%
Max EPS beat(2)12.62%
EPS beat(4)2
Avg EPS beat(4)-7.57%
Min EPS beat(4)-55.11%
Max EPS beat(4)29.84%
EPS beat(8)5
Avg EPS beat(8)4.34%
EPS beat(12)8
Avg EPS beat(12)-10.32%
EPS beat(16)10
Avg EPS beat(16)-9.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)125%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.62%
EPS NY rev (1m)0%
EPS NY rev (3m)18.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.08
P/tB 7.08
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -184.8%
ROE -582.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z -62.57
F-Score2
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.4%
EPS Next Y53.09%
EPS Next 2Y32.34%
EPS Next 3Y21.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A
EBIT growth 1Y-49.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.28%
OCF growth 3YN/A
OCF growth 5YN/A

SOLIGENIX INC / SNGX FAQ

Can you provide the ChartMill fundamental rating for SOLIGENIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to SNGX.


Can you provide the valuation status for SOLIGENIX INC?

ChartMill assigns a valuation rating of 1 / 10 to SOLIGENIX INC (SNGX). This can be considered as Overvalued.


What is the profitability of SNGX stock?

SOLIGENIX INC (SNGX) has a profitability rating of 0 / 10.


What is the expected EPS growth for SOLIGENIX INC (SNGX) stock?

The Earnings per Share (EPS) of SOLIGENIX INC (SNGX) is expected to grow by 53.09% in the next year.